Variable |
Yoga (n=7) |
Resistance (n=7) |
p-value |
Chicago (n=9) |
LF (n=5) |
p-value |
Age (yrs) |
67.9 (SD 10.9) |
66.7 (SD 9.3) |
0.83 |
65.4 (SD 10.0) |
70.6 (SD 9.6) |
0.37 |
Gender (M/F) |
5/2 |
6/1 |
n/a |
6/3 |
5/0 |
n/a |
Race (White/Non-white) |
6/1 |
5/2 |
n/a |
7/2 |
4/1 |
n/a |
Baseline H&Y |
2.3 (SD 0.4) |
2.4 (SD 0.5) |
0.61 |
2.3 (SD 0.5) |
2.4 (SD 0.5) |
0.83 |
Baseline LED |
328 (SD 255) |
486 (SD 478) |
0.46 |
369.4 (SD 196.4) |
476 (SD 614.0) |
0.72 |
Baseline MOCA |
26.8 (SD 1.77) |
26.8 (SD 1.77) |
1 |
26.5 (SD 1.6) |
27.4 (SD 1.9) |
0.43 |
Baseline BDI |
4.57 (SD 4.54) |
7.57 (SD 3.35) |
0.18 |
6.2 (SD 4.6) |
5.8 (SD 3.4) |
0.85 |
Baseline TUG (sec) |
9.86 (SD 2.11) |
10.04 (SD 1.17) |
0.85 |
9.7 (SD 1.7) |
10.4 (SD 1.5) |
0.47 |
Baseline BBS |
52.28 (SD 2.92) |
52.71 (SD 2.69) |
0.78 |
53.2 (SD 2.28) |
51.2 (SD 3.2) |
0.25 |
Baseline UPDRS III |
25.85 (SD 6.91) |
22.57 (SD 7.23) |
0.4 |
24.1 (SD 6.5) |
24.4 (SD 8.7) |
0.95 |
Baseline UPDRS Total |
36.43 (SD 9.94) |
35.49 (SD 8.69) |
0.84 |
35.3 (SD 8.9) |
37.0 (SD 10.0) |
0.77 |
Baseline PDQ-39 |
20.00 (SD 22.55) |
21.14 (SD 9.47) |
0.9 |
23.1 (SD 18.1) |
16 (SD 14.1) |
0.43 |
Baseline FES-1 |
23.14 (SD 6.06) |
21.85 (SD 4.33) |
0.65 |
22.0 (SD 5.8) |
23.4 (SD 4.0) |
0.61 |
Baseline FOG |
2.71 (SD 2.62) |
3.14 (SD 3.43) |
0.79 |
3.0 (SD 2.8) |
2.8 (SD 3.5) |
0.91 |
Baseline FF |
1.28 (SD 1.38) |
0.86 (SD 0.89) |
0.51 |
1.2 (SD 1.3) |
0.8 (SD 0.8) |
0.47 |
|
There are no significant differences in baseline clinical characteristics between yoga and resistance groups or between Chicago and Lake Forest groups. The majority of
the participants were white males.
H&Y=Hoehn & Yahr; LED=Levodopa Equivalent Dose, calculated based on the formula reported by Tomlinson et al [36]; MOCA=Montreal Cognitive Assessment; BDI=Beck
Depression Inventory; TUG=Timed-Up-And-Go; BBS=Berg Balance Scale; UPDRS=Unified Parkinson Disease Rating Scale; PDQ-39=Parkinson Disease Questionnaire;
FES-1=Falls Efficacy Scale; FOG=Giladi Freezing of Gait Scale; FF=Fall Frequency Scale |
Table 1: Baseline demographics. |